PHA/RMA News
Indian Blue-Chips Post Broad Volume Surge as Risk-On Sentiment Drives Nifty 50 Participation
Indian blue-chip stocks including Sun Pharma, HDFC Life, Tata Steel, and Bajaj Finance showed notable volume activity
Jun 15, 2026
๐ญ๐ฐ Hong KongAscentage Pharma Advances Hematology Pipeline at EHA2026 on Dual NASDAQ-HKEX Platform
Ascentage Pharma presented olverembatinib and lisaftoclax clinical updates at EHA2026, advancing its dual-listed hematology pipeline toward regulatory submissions.
Jun 15, 2026
๐บ๐ธ United StatesProtagonist Therapeutics: Two FDA Catalyst Shots With Royalty Income and Cash Runway Through 2028
Protagonist Therapeutics holds two royalty-generating FDA catalyst programmes with strong cash runway through 2028
Jun 14, 2026
๐ฎ๐ณ IndiaYES Securities Picks Entero Healthcare, Maruti Suzuki, Lupin as June 2026 Market Beaters
YES Securities picks Entero Healthcare, Maruti Suzuki, Lupin as top 3 market-beating India stocks for June 2026
Jun 14, 2026
๐บ๐ธ United StatesIncyte Nears Buy Point as $1.25B Acquisition Broadens Drug Pipeline
Incyte Corporation is approaching a key technical buy point following its $1.25 billion acquisition that meaningfully expands the company's pharmaceutical pipeline.
Jun 12, 2026
๐บ๐ธ United StatesEnliven Therapeutics Surges on Clinical-Stage Oncology Pipeline Interest and Biotech Momentum
Enliven Therapeutics (ELVN) saw a significant price surge driven by clinical-stage oncology pipeline momentum and broader biotech sector activity.
Jun 12, 2026
๐บ๐ธ United StatesPropanc Biopharma Launches $5M Share Buyback, Signalling Management Confidence in Oncology Pipeline
Propanc Biopharma launched a $5 million share repurchase program, signalling management confidence in the oncology company's current valuation.
Jun 12, 2026
๐จ๐ณ ChinaKolonbo Tech Receives 600M Yuan Settlement from Yilun Biopharma in Chinese Biotech Dispute
Kolonbo Tech received over 600 million yuan in settlement from Yilun Biopharma, resolving a major commercial dispute.
Jun 12, 2026
๐บ๐ธ United StatesEnliven Therapeutics ELVN Surges on Positive Phase 1 Trial Results as Clinical De-Risking Drives Rally
Enliven Therapeutics (ELVN) surged after reporting positive Phase 1 clinical trial results, demonstrating early evidence of safety and preliminary efficacy signals for its lead therapeutic candidate.
Jun 12, 2026
๐บ๐ธ United StatesCOPL Enters Merger Agreement with Ignite Proteomics to Create New Public Biotech Entity
COPL (Canadian Overseas Petroleum) has entered a merger agreement with Ignite Proteomics to create a new public entity.
Jun 12, 2026
๐จ๐ณ ChinaHong Kong Biotech Evolves Beyond Listing Hub Into Innovation Center Amid China Biopharma Surge
Hong Kong's biotech sector has transitioned from a capital-raising venue to an active biopharma product hub.
Jun 11, 2026
๐บ๐ธ United StatesParabilis Medicines (PBLS) Surges Over 45% in Record IPO Debut on Nasdaq
Parabilis Medicines (PBLS) surged over 45% in its Nasdaq IPO debut, delivering a strong biotech first-day performance.
Jun 11, 2026
๐ฐ๐ท South KoreaKorean Scientists Crack Argonaute Activation Mechanism, Opening New Path for RNA Therapeutics Design
Korean scientists at IBS and Seoul National University identified the activation mechanism of the Argonaute protein, a key step in RNA therapeutic design.
Jun 11, 2026
๐จ๐ฆ CanadaMindWalk Holdings Launches ReefIQ Biological Context Platform for AI Drug Discovery
MindWalk Holdings Corp (NASDAQ: HYFT) launched ReefIQ, a biological context layer that makes fragmented biological data queryable for AI-powered drug discovery.
Jun 11, 2026
๐จ๐ณ ChinaChinese Pharma Cost Advantages Outweigh Pentagon Blacklisting of WuXi AppTec: Analysts
Jefferies analysts say multinational pharma will continue working with Chinese firms like WuXi AppTec despite the Pentagon blacklisting, as cost advantages remain too significant to abandon.
Jun 10, 2026
๐จ๐ฆ CanadaKARL STORZ Wins FDA Clearance for Rubina Lens Exoscope, Expanding NIR Imaging Ecosystem
KARL STORZ received FDA clearance for the Rubina Lens exoscope for open surgery, extending its NIR/ICG imaging ecosystem across both open and minimally invasive procedures.
Jun 10, 2026
๐จ๐ฆ CanadaTeva Closes Emalex Biosciences Acquisition to Strengthen Neuroscience Pipeline With First-in-Class Tourette Drug
Teva Pharmaceuticals closed its acquisition of Emalex Biosciences, adding ecopipam โ a first-in-class D1 receptor antagonist for pediatric Tourette syndrome โ to its pipeline.
Jun 10, 2026
๐ฉ๐ช GermanyGerman Government Coalition Moves to Shield Pharma Industry From Billions in Austerity Spending Cuts
Germany's ruling coalition is working on relief measures for the pharmaceutical industry within its planned healthcare austerity law, according to Handelsblatt.
Jun 10, 2026
๐ฎ๐ณ IndiaGSK Acquires Nuvalent for $10.6 Billion as Shares Surge 39% to $123 on Precision Oncology Bet
GlaxoSmithKline agreed to acquire Nuvalent for $10.6 billion, sending shares surging 39% to $123 as GSK expands its precision oncology portfolio with ROS1/ALK cancer therapies.
Jun 10, 2026
๐จ๐ฆ CanadaFDA Catalyst Puts Conexeu Sciences and Regenerative Wound Care in Market Focus
A fresh FDA catalyst is placing Conexeu Sciences and the broader regenerative wound care sector in investor focus, signaling concrete regulatory progress for the clinical-stage firm.
Jun 10, 2026
๐ฌ๐ง United KingdomWeight Loss Drug Surge Starts Hitting UK Supermarket Sales as 'Small Appetites' Economy Emerges
A surge in weight loss drug use is measurably hitting UK supermarket sales as GLP-1 users consume significantly less, creating a structural demand shift for food retail.
Jun 10, 2026
๐บ๐ธ United StatesNuvalent (NUVL) Surges 38.8% Pre-Market as All-Cash Acquisition Offer Drives Rapid Market Re-Pricing
Nuvalent surged 38.8% ahead of market open as an all-cash acquisition offer triggered rapid re-pricing to deal value, with merger arbitrageurs locking in the residual spread.
Jun 10, 2026
๐บ๐ธ United StatesNuvalent (NUVL) Surges 38.8% to Record High on GSK's $10.6 Billion All-Cash Acquisition Bid
Nuvalent shares surged 38.8% to a record high after GSK made a $10.6 billion all-cash bid, with the all-cash structure removing deal risk for Nuvalent shareholders.
Jun 10, 2026
๐บ๐ธ United StatesGSK Faces Investor Pressure After $10.6 Billion Nuvalent Acquisition Draws Market Scrutiny
GSK faces investor pressure following its $10.6 billion acquisition of Nuvalent as the market assesses deal premium dilution and near-term earnings impact.
Jun 10, 2026
๐ธ๐ฌ SingaporeGSK Acquires Nuvalent for $10.6 Billion at $124 per Share in Oncology Expansion
GSK will acquire Nuvalent for $10.6 billion, paying $124 per share to expand its cancer drug pipeline in a high-premium oncology acquisition.
Jun 10, 2026
๐ฎ๐ณ IndiaIndia's Cancer Drug Shortage Deepens as Platinum Costs and Import Disruptions Squeeze Manufacturers
Cancer patients in India face shortages of key chemotherapy drugs as surging platinum costs and import disruptions constrain domestic pharmaceutical manufacturers.
Jun 10, 2026
๐ฎ๐ณ IndiaIndia Cancer Drug Shortage as Platinum Cost Surge Disrupts Cisplatin Supply Chain
Indian cancer patients are facing acute shortages of cisplatin and other platinum-based drugs as surging platinum costs disrupt pharmaceutical supply chains.
Jun 10, 2026
๐จ๐ณ ChinaAlibaba and WuXi AppTec Fall in Hong Kong After US Adds Both to Military Ties Blacklist
Alibaba slipped 0.3% to HK$118.50 and WuXi AppTec tumbled 5.5% to HK$114.60 after both were added to the US military-ties blacklist.
Jun 10, 2026
๐บ๐ธ United StatesGSK Eyes 10 Billion Nuvalent Acquisition in Strategic Bet on Precision Oncology
GSK is exploring an acquisition of Nuvalent at a valuation of up to $10 billion, per reports.
Jun 9, 2026
๐บ๐ธ United StatesEli Lilly Makes 3 Infectious Disease Acquisitions in One Day, Signaling Post-Obesity Growth Push
Eli Lilly announced three infectious disease acquisitions in a single day, targeting its next growth platform.
Jun 9, 2026